Advanced

Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan-two case studies.

Jerkeman, Mats LU and Lindén, Ola LU (2015) In European Journal of Haematology
Abstract
Multicentric Castleman's disease (MCD) is an uncommon lymphoproliferative disorder, often associated with a clinically aggressive behavior. No standard treatment has been established, but patients are usually treated with lymphoma-type regimens such as rituximab or combination chemotherapy. Recently, immunotherapies targeting IL-6 have proven effective and have been approved for this indication. However, these agents require long-term administration. Here, we describe the clinical course of two patients, refractory to rituximab and chemotherapy, showing long-term remission (18 and 24 months), following an induction phase with tocilizumab (an anti-IL-6 receptor antibody) and a consolidative phase with high-dose melphalan accompanied by... (More)
Multicentric Castleman's disease (MCD) is an uncommon lymphoproliferative disorder, often associated with a clinically aggressive behavior. No standard treatment has been established, but patients are usually treated with lymphoma-type regimens such as rituximab or combination chemotherapy. Recently, immunotherapies targeting IL-6 have proven effective and have been approved for this indication. However, these agents require long-term administration. Here, we describe the clinical course of two patients, refractory to rituximab and chemotherapy, showing long-term remission (18 and 24 months), following an induction phase with tocilizumab (an anti-IL-6 receptor antibody) and a consolidative phase with high-dose melphalan accompanied by autologous stem cell support. This may prove to be an effective option for this group of patients with an orphan disorder. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
European Journal of Haematology
publisher
Wiley-Blackwell
external identifiers
  • pmid:26256458
  • scopus:84940055412
  • wos:000374147300012
ISSN
1600-0609
DOI
10.1111/ejh.12646
language
English
LU publication?
yes
id
bb4778b6-2f94-4066-9216-85f1011a7cc5 (old id 7844335)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26256458?dopt=Abstract
date added to LUP
2015-09-05 16:43:12
date last changed
2017-02-05 04:32:51
@article{bb4778b6-2f94-4066-9216-85f1011a7cc5,
  abstract     = {Multicentric Castleman's disease (MCD) is an uncommon lymphoproliferative disorder, often associated with a clinically aggressive behavior. No standard treatment has been established, but patients are usually treated with lymphoma-type regimens such as rituximab or combination chemotherapy. Recently, immunotherapies targeting IL-6 have proven effective and have been approved for this indication. However, these agents require long-term administration. Here, we describe the clinical course of two patients, refractory to rituximab and chemotherapy, showing long-term remission (18 and 24 months), following an induction phase with tocilizumab (an anti-IL-6 receptor antibody) and a consolidative phase with high-dose melphalan accompanied by autologous stem cell support. This may prove to be an effective option for this group of patients with an orphan disorder.},
  author       = {Jerkeman, Mats and Lindén, Ola},
  issn         = {1600-0609},
  language     = {eng},
  month        = {08},
  publisher    = {Wiley-Blackwell},
  series       = {European Journal of Haematology},
  title        = {Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan-two case studies.},
  url          = {http://dx.doi.org/10.1111/ejh.12646},
  year         = {2015},
}